<SEC-DOCUMENT>0001144204-18-030165.txt : 20180522
<SEC-HEADER>0001144204-18-030165.hdr.sgml : 20180522
<ACCEPTANCE-DATETIME>20180522070033
ACCESSION NUMBER:		0001144204-18-030165
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180518
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180522
DATE AS OF CHANGE:		20180522

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		18851272

	BUSINESS ADDRESS:	
		STREET 1:		617 DETROIT STREET, SUITE 100
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48104
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv494744_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
May 18, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 34%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-12584</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-3808303</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File No.)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">9605 Medical Center Drive, Suite 270</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rockville, MD 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices
and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (301) 417-4364</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 3.01 Notice of delisting or Failure to Satisfy a Continued
Listing Rule or Standard: Transfer of Listing.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As previously disclosed, on March 2, 2018,
Synthetic Biologics, Inc. (the &ldquo;Company&rdquo;) received notification (the &ldquo;Deficiency Letter&rdquo;) from the NYSE
American LLC (the &ldquo;NYSE American&rdquo;) that it was not in compliance with certain NYSE American continued listing standards
relating to stockholders&rsquo; equity as of December 31, 2017. Specifically, the Deficiency Letter stated that the Company is
not in compliance with Section 1003(a)(i) (requiring stockholders&rsquo; equity of $2.0 million or more if it has reported losses
from continuing operations and/or net losses in two its three most recent fiscal years), Section 1003(a)(ii) (requiring stockholders&rsquo;
equity of $4.0 million or more if it has reported losses from continuing operations and/or net losses in three of its four most
recent fiscal years); and Section 1003(a)(iii) (requiring stockholders&rsquo; equity of $6.0 million or more if it has reported
losses from continuing operations and/or net losses in its five most recent fiscal years). The Deficiency Letter noted that the
Company had a stockholders&rsquo; equity deficit of $(1,500,000) as of December 31, 2017, and has reported net losses in its five
most recent fiscal years. The Company was required to submit a plan to the NYSE American by April 3, 2018 advising of actions it
has taken or will take to regain compliance with the continued listing standards by September 2, 2019.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 18, 2018, the Company received notice
from the NYSE American that it had accepted the Company&rsquo;s plan and granted a plan period through September 2, 2019. During
the plan period the Company will be subject to periodic review to determine if it is making progress consistent with the plan.
If the Company does not regain compliance with the NYSE American listing standards by September 2, 2019, or if the Company does
not make sufficient progress consistent with its plan, then the NYSE American may initiate delisting proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 22, 2018, the Company issued a press release disclosing
the receipt of the NYSE American notice accepting its plan, a copy of which is attached hereto as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01. Financial Statements and Exhibits </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exhibits.</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 15%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 5%; border-bottom: white 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 80%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center"><A HREF="tv494744_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv494744_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release issued May 22, 2018.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: May 22, 2018</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven A. Shallcross</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Steven A. Shallcross</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Interim Chief Executive Officer and Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 15%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 80%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="tv494744_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">99.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv494744_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Press release issued by Synthetic Biologics, Inc. dated May 22, 2018</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv494744_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image_004.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 387.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 387.75pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Synthetic Biologics Announces Acceptance
of Compliance Plan by NYSE American</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rockville, MD, May 22, 2018 &ndash;</B>
Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the
microbiome to protect and restore the health of patients, announced today that the NYSE American LLC (the &ldquo;Exchange&rdquo;)
has accepted the Company&rsquo;s plan of compliance (the &ldquo;Plan&rdquo;) for continued listing on the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As previously reported, on March 2, 2018,
Synthetic Biologics received a letter from NYSE American Staff indicating that the Company is not in compliance with certain continued
listing standards relating to stockholders equity as set forth in Part 10, Section 1003 of the NYSE American Company Guide (the
&ldquo;Guide&rdquo;). Based on the Company&rsquo;s 2017 annual report on Form 10-K, the Company is below compliance with Part 10,
Section 1003(a)(iii) of the Guide since it reported stockholders&rsquo; equity of less than $6 million and net losses in five of
its most recent fiscal years as of December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with NYSE American&rsquo;s
policies and procedures, the Company submitted its plan of compliance on April 3, 2018 addressing how the Company intends to regain
compliance with Part 10, Section 1003 of the Guide. On May 18, 2018, the Exchange notified Synthetic Biologics that it accepted
the Company&rsquo;s compliance plan and granted the Company an extension until September 2, 2019 (the &ldquo;Plan Period&rdquo;).
Synthetic Biologics will be subject to periodic review by Exchange Staff during the Plan Period. If the Company dos not regain
compliance by the end of the Plan Period, or if the Company does not make progress consistent with its Plan, the Exchange may initiate
delisting procedures as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The notice of acceptance from NYSE American
does not affect the Company&rsquo;s business operations or the listing of the Company&rsquo;s common stock on the Exchange, which
will continue to trade under the symbol &ldquo;SYN&rdquo;, subject to periodic review by the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE American:
SYN) is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of
patients. The Company's lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect
the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of <I>C.
difficile</I> infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR), and (2)
SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause
of irritable bowel syndrome with constipation (IBS-C). The Company&rsquo;s preclinical pursuits include an oral formulation of
the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases as well as monoclonal antibody therapies
for the prevention and treatment of pertussis, and novel discovery stage biotherapeutics for the treatment of phenylketonuria
(PKU). For more information, please visit Synthetic Biologics' website at <U>www.syntheticbiologics.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements
can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot; &quot;expects,&quot;
&quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot; and similar expressions,
and include statements regarding Synthetic Biologics&rsquo;intent to regain compliance with Part 10, Section 1003 of the Guide
and the potential benefits of SYN-004 and SYN-010.&nbsp;These forward-looking statements are based on management's expectations
and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are
difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those
set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially
from current expectations include, among others, Synthetic Biologics&rsquo; ability to regain compliance with the continued listing
standards by September 2, 2019, Synthetic Biologics&rsquo; ability to comply with other continued listing requirements of the NYSE
American, a failure to receive the necessary regulatory approvals for commercialization of Synthetic Biologics' therapeutics, a
failure of Synthetic Biologics' clinical trials, and those conducted by investigators, for SYN-004 and SYN-010 to be commenced
or completed on time or to achieve desired results and benefits, a failure of Synthetic Biologics' clinical trials to continue
enrollment as expected or receive anticipated funding, a failure of Synthetic Biologics to successfully develop, market or sell
its products, Synthetic Biologics' inability to maintain its material licensing agreements, or a failure by Synthetic Biologics
or its strategic partners to successfully commercialize products and other factors described in Synthetic Biologics' most recent
Form 10-K and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this
release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking
statements contained in this release on account of new information, future events, or otherwise, except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (Corporate and
Investors)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vincent I. Perrone, Director, Corporate Communication, (240)
660-2000, <U>info@syntheticbiologics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Feinstein Kean Healthcare (Media)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gregory Kelley, Senior Vice President, (404) 836-2302, <U>gregory.kelley@fkhealth.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">###</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !1 1T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
